🧾 What This Document Is

This is a Definitive Proxy Statement (DEF 14A) for Acumen Pharmaceuticals. Think of it as an invitation and a voter's guide for the company's 2026 Annual Meeting of Stockholders. It explains what will be voted on, provides background on the company's leaders and pay, and gives financial details. Stockholders use it to make informed decisions before casting their votes.

🏢 What The Company Does

👉 In simple terms… Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company. They are focused on developing new drugs for Alzheimer's disease, a major cause of dementia. This means they are in the research and testing phase, not yet selling any approved products. Their work is high-risk and high-reward, typical for biotech firms tackling complex brain diseases.

📅 The Big Vote: Meeting & Proposals

The Annual Meeting will be held virtually on Wednesday, June 3, 2026, at 11:00 a.m. Eastern Time. Stockholders will vote on three main items:

1. Elect Three Directors: You're voting for George Golumbeski, Ph.D., Derrell Porter, M.D., and Laura Stoppel, Ph.D. to join the Board. If elected, they'll serve until 2029.
   • 👉 Why it matters: The Board oversees the company's direction and management. These nominees bring expertise in drug development, medicine, and science.
2. Ratify the Auditor: Approve Ernst & Young LLP as the independent accounting firm for 2026.
   • 👉 Why it matters: This is a standard check on the company's financial reporting. Ernst & Young has been their auditor since 2021.
3. Approve the Equity Plan: Give the green light to the Amended and Restated 2021 Equity Incentive Plan. This is a significant proposal to expand the company's "toolbox" for rewarding employees and directors with stock.
   • 👉 Why it matters: It adds 10,000,000 new shares to the plan for future awards, which can dilute existing shareholders. The company argues it's essential to attract and retain talent in the competitive biotech industry.

👥 Board & Governance

The Board is led by an independent Chair, Dr. George Golumbeski, separate from the CEO, Daniel O'Connell. The Board has determined that 7 of its 10 members are independent, which is a good governance practice. They have key committees (Audit, Compensation, Nominating) with specific oversight roles. The company has a Code of Ethics and Corporate Governance Guidelines available on its website.

• Director Nominees (Class II):
  • George Golumbeski, Ph.D. (Chair): Expertise in drug development & biotech leadership.
  • Derrell Porter, M.D. (Nominee): Background in medicine and biotech venture capital.
  • Laura Stoppel, Ph.D. (Nominee): Experience in neuroscience and drug discovery.
• Continuing Directors: Include CEO Daniel O'Connell, and other experts in neurology, finance, and venture capital.

💼 Executive Compensation

The filing details how much the top executives were paid in 2025. For a clinical-stage company like Acumen, compensation is heavily weighted towards stock awards (options and RSUs) rather than large cash salaries. This aligns executive pay with the company's long-term success and stock price performance. The exact figures for named executives are listed in the "Summary Compensation Table."

💸 The Equity Plan Deep Dive (Proposal 3)

This is a major focus of the document. The company wants to:

• Add 10,000,000 shares to its 2021 Equity Incentive Plan.
• Remove the "evergreen" provision that automatically increased shares each year.
• Prohibit repricing of options without shareholder approval.

👉 Why it matters: This plan is how the company pays and incentivizes its team. The proposed increase is substantial.

• Potential Dilution: If approved, total potential dilution (shares for outstanding awards + new shares available) would be 40.2% of current outstanding shares. That's a significant increase from the current 26.4%.
• Company's Justification: They say the new shares are needed for about two years to continue attracting talent. They point to their "burn rate" (how quickly they use shares) of 6.0% over the last three years as evidence of responsible management.

⚖️ Financial Oversight & Fees

The Audit Committee oversees financial reporting. Stockholders are asked to ratify the choice of Ernst & Young LLP as auditor. For 2025, total fees paid to EY were $732,000 ($659k for audit, $73k for tax services). The committee pre-approves all services to ensure auditor independence.

🌍 What's Next & Strategic Context

After the June 3 vote, the newly constituted Board will continue to oversee Acumen's progress in its clinical trials for Alzheimer's treatments. Approval of the equity plan is crucial for their talent strategy. The company is in a critical, cash-burning phase of development, with success heavily dependent on clinical trial outcomes. The proxy statement signals a focus on maintaining a skilled team through equity incentives as they pursue this goal.

⚖️ Big Picture

👍 Strengths:

• Experienced Board: Nominees and continuing directors have deep expertise in neuroscience, drug development, and biotech management.
• Standard Governance Practices: Independent Chair, majority-independent Board, and established committees.
• Transparent Compensation: Executive pay is clearly tied to long-term company performance via equity.

⚠️ Risks:

• High Dilution: The equity plan approval would lead to substantial potential dilution for existing shareholders (40.2%).
• Clinical-Stage Risk: The company has no approved products or revenue from sales. Its value hinges entirely on the success of its research pipeline.
• Dependence on Talent & Capital: Success requires retaining key scientists and executives (via the equity plan) and securing ongoing funding.

🧠 The Analogy

Think of this proxy statement as the annual report card and action plan for a high-stakes science project. You, the shareholder, are a backer. The document shows you who is running the project (the Board), how they are paying the lead scientists (Executive Comp), and asks you to approve a new budget for rewarding the team (Equity Plan). You're voting on whether to keep the current team leads (Directors) and the project's financial auditor. Your decision shapes the resources and oversight for the next phase of risky, potentially groundbreaking work.

🧩 Final Takeaway

This is your vote as a shareholder on Acumen's leadership and its plan to use company stock to reward its team. The key decision is Proposal 3, which could significantly increase the number of shares available for awards, diluting your stake but which the company argues is vital for its race to develop an Alzheimer's drug.